Exelixis, Inc.(EXEL)Earnings, Financials & Key RatiosExelixis, Inc. (EXEL) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the company maintains a healthy balance sheet and a 15.55 forward P/E ratio, the material risk of generic litigation and volatile cash flow generation warrants a cautious approach.
Exelixis, Inc. (EXEL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Exelixis, Inc. (EXEL) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.87vs $0.77+13.7% | $611Mvs $608M+0.5% |
| Q1 2026 | Feb 10, 2026 | $0.94vs $0.77+22.1% | $599Mvs $597M+0.4% |
| Q4 2025 | Nov 4, 2025 | $0.78vs $0.69+13.9% | $598Mvs $590M+1.3% |
| Q3 2025 | Jul 28, 2025 | $0.75vs $0.65+15.4% | $568Mvs $595M-4.5% |
Recent stock market news and headlines for Exelixis, Inc. (EXEL)
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Exelixis falls after STELLAR-303 misses statistical significance in overall survival for a key colorectal cancer subgroup, raising approval uncertainty.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from the final analysis of the dual primary endpoint of overall survival (OS) in the subset of patients without active liver metastases (non-liver metastases, NLM) in the phase 3 STELLAR-303 pivotal trial evaluating zanzalintinib in combination with atezolizumab (Tecentriq®) versus regorafenib in previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC).
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Key metrics vs top competitors for Exelixis, Inc. (EXEL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $57.08 | $14.5B | 20.53 | 6.98% | 33.73% | 35.53% | — | |
| $118.05 | $23.58B | 18.42 | 21.22% | 26.71% | 29.31% | — | |
| $55.22 | $9.2B | 38.62 | -5.25% | 9.78% | 8.82% | — | |
| $247.72 | $15.54B | -42.42 | 4.88% | 0.66% | 0.71% | — | |
| $86.33 | $14.27B | -36.27 | 33.87% | -30.87% | -58.57% | — | |
| $81.57 | $9.68B | 31.86 | 37.55% | 23.13% | 126.27% | — |
Exelixis, Inc. (EXEL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Exelixis, Inc. (EXEL) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 5, 2026·SEC
Feb 10, 2026·SEC
Jan 12, 2026·SEC
Get notified when EXEL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Exelixis, Inc. (EXEL) stock FAQ — growth, dividends, profitability & financials explained
Exelixis, Inc. (EXEL) reported $2.38B in revenue for fiscal year 2025. This represents a 22524% increase from $10.5M in 1999.
Exelixis, Inc. (EXEL) grew revenue by 7.0% over the past year. This is steady growth.
Yes, Exelixis, Inc. (EXEL) is profitable, generating $833.4M in net income for fiscal year 2025 (33.7% net margin).
Exelixis, Inc. (EXEL) has a return on equity (ROE) of 35.5%. This is excellent, indicating efficient use of shareholder capital.
Exelixis, Inc. (EXEL) generated $918.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
